Vial label design and print may vary between batches. Product specifications remain unchanged.
At a glance
Strength
10mg per vial
Form
Lyophilised powder
Purity
≥ 99% (HPLC)
CAS number
86168-78-7
Molecular weight
3357.9 g/mol
Certificate of Analysis
Batch SER-10-28 · Prime Peptides UK
Growth hormone secretagogues
Sermorelin
Synthetic research peptide · 10mg · CAS 86168-78-7
£39.95 In stock · ready to shipper vial · £4.00 per mg
Sermorelin 10mg is coming soon. It goes on sale as soon as its batch certificate is published - every vial we sell has a matching CoA.
Bank transferBitcoin Encrypted checkout · card details are never taken on this site
Multi-item discount. Add any 2 items for 4% off the whole order, 7% at 3, 10% at 4. Applied automatically at checkout.
Free
Free lab add-on. Bacteriostatic water is included with every peptide order at no extra cost.
Lab essentials tap to add to this order
RUOResearch Use Only. Not for human or veterinary use. By purchasing you confirm you are a qualified researcher and accept responsibility for safe, lawful handling.
Same-day dispatch
Orders before 3:00 PM leave the same working day, tracked, in plain packaging. Free UK delivery over £200.
Secure payment
Bank transfer or Bitcoin over an encrypted checkout. No card details are stored or handled on this site.
Batch tested
Every batch is HPLC and mass spectrometry tested, and its certificate is published before it ships.
Sermorelin 10mg≥99% HPLC · In stock
£39.95
Compound Overview
What Is Sermorelin 10mg?
Sermorelin 10mg is a laboratory research peptide version of a synthetic 29 amino acid peptide that is the biologically active N-terminal fragment of human growth hormone-releasing hormone (GHRH). The peptide has been studied in relation to the GHRH receptor and growth-hormone signalling. This 10mg presentation supplies a specified amount of research material for controlled laboratory and analytical activities. It is only provided for scientific research and not for human consumption, self-administration or therapeutic purposes.
Sermorelin is the commonly used name for growth hormone-releasing hormone (1-29) amide, also written as GHRH(1-29)NH₂ or GRF(1-29)NH₂. It consists of the first 29 amino acids of naturally occurring human GHRH, a 44-amino-acid hypothalamic peptide. These first 29 residues retain biological activity associated with the parent hormone, making the shorter sequence useful in research examining GHRH receptor biology and related signalling.
The established amino-acid sequence of sermorelin is
YADAIFTNSYRKVLGQLSARKLLQDIMSR
The growth of scientific research around the regulation of growth hormone, binding to growth hormone receptors, as well as the significance of the structure–activity relationships of peptides derived from GHRH, has thus led to the appearance of Sermorelin in scientific publications.
For this product, 10mg only applies to the amount of research material provided. It is not a recommended dose. Sermorelin 10mg UK research material is designed for well-equipped research labs and experienced research environments with their own approved research protocol.
Technical Data
Sermorelin Product Specifications
Technical Specification Sheet
SERMORELIN · 10MG · RUO
Product Name
Sermorelin 10mg
Compound
Sermorelin / GHRH(1-29)-NH₂
Strength
10mg
Peptide Length
29 amino acids
Sequence
YADAIFTNSYRKVLGQLSARKLLQDIMSR
Molecular Formula
C149H246N44O42S
Molecular Weight
Approx. 3357.9 g/mol
Format
Research peptide material
Classification
GHRH-derived peptide
Documentation
Batch-specific COA where provided
Intended Use
Laboratory and scientific research only
CAS Number
86168-78-7
Purity
≥99% by HPLC
Analytical documentation should always be checked against the batch supplied rather than assuming specifications from general information about the compound.
The Science
Scientific Background: From GHRH to Sermorelin
hGH-RH is synthesized in the hypothalamus and is involved in signals involved in controlling the release of growth hormone from the anterior pituitary. Sermorelin is the N-terminal fragment (1–29) of this natural 44-amino-acid peptide.
This difference is of significance to science. Sermorelin is not growth hormone! Rather, experimental literature has focused on it as a GHRH-derived peptide that interacts with the physiological signalling pathway preceding growth hormone secretion.
Investigations with GHRH(1-29) have helped to elucidate receptor-mediated signalling, structure–activity relationships of peptides and the significance of specific amino-acid regions for the biological activity of GHRH. The stability of the fragments of GHRH and the potential effect of structural changes on experimental behaviour have also been investigated.
Research Context
Historical studies involve laboratory investigation and studies as well as clinical studies. The above studies, however, cannot be viewed as proof a research-labelled product is a registered drug. Research compounds are different from authorised medicinal products in terms of their regulatory, quality and intended-use contexts.
Laboratory Focus
Why Is Sermorelin Studied in Research?
Sermorelin provides researchers with a defined peptide sequence representing the biologically active N-terminal region of GHRH. This makes it relevant to several areas of experimental investigation.
Growth Hormone Axis
One area concerns GHRH receptor signalling. Laboratory models can be used to explore how peptide–receptor interactions initiate downstream cellular responses and how changes in peptide structure alter those interactions.
Receptor Signalling
Sermorelin has also been used in research investigating the growth hormone regulatory axis. Such work has helped scientists study relationships between hypothalamic signalling, pituitary responses and downstream endocrine processes.
Growth Hormone Axis
Another field involves peptide stability and degradation. GHRH-derived peptides are susceptible to enzymatic breakdown, and experimental studies have investigated structural approaches intended to modify peptide stability or biological persistence.
Receptor Signalling
Sermorelin is additionally relevant to structure–activity research, where researchers compare sequences or modified analogues to determine which structural features contribute to receptor interaction and biological activity. These research areas describe scientific investigation rather than established benefits of Sermorelin 10mg for individuals.
Product Format
Understanding the 10mg Research Format
10mg
Nominal Research Quantity
The 10mg means the total nominal amount of Sermorelin research material per product format. It is not a dose or recommendation for an individual or species of animals or humans.
A controlled 10mg research format might be applicable, as different laboratories have different needs for experimental material. Requirements depend on factors including study design, number of analytical runs, assay configuration, replication requirements and the scale of a research programme.
For instance, if a project has a number of analytical phases, the material needs will be varied from those needed for a limited analytical preliminary assay. Researchers evaluate the product's quantity by comparing it to the documented protocol, not by comparing the milligram amount to effectiveness or potency.
This distinction is special when comparing the different forms of Sermorelin products. 10mg refers to the quantity of research supplied, NOT superiority, safety, or therapeutic effectiveness.
All experimental quantities and laboratory procedures should be set by qualified researchers who are capable of doing so and according to validated institutional procedures.
Verification
Quality Testing, Peptide Identity and Certificate of Analysis
Peptide sourcing requires more than checking the compound name printed on a vial. Researchers should be able to evaluate analytical information connected with the material they receive.
HPLC Analysis
High-performance liquid chromatography (HPLC) may be used to assess chromatographic purity, while complementary analytical techniques can help establish molecular identity. Importantly, purity and identity are related but separate questions: a high reported chromatographic purity does not by itself establish that a sample contains the intended peptide.
Batch-Specific CoA
A Certificate of Analysis (COA) can provide useful batch-level information. Researchers should check whether the document identifies the compound, batch or lot number, analytical method, reported result and relevant testing date.
Documentation & Transparency
Where independent laboratory testing is stated, documentation should allow the claim to be evaluated rather than relying solely on promotional wording.
For Sermorelin 10mg, analytical results should always be interpreted in relation to the specific batch supplied, since general information about sermorelin cannot establish the characteristics of an individual research batch.
Handling
Storage and Laboratory Handling
Environmental Conditions
Peptides can be sensitive to environmental conditions, so Sermorelin research material should be handled according to the storage information accompanying the specific product and the laboratory’s standard operating procedures.
Labelling & Traceability
The material should remain in its original labelled container where practical, with the batch identity retained for traceability. Exposure to unnecessary heat, moisture and direct light should be minimised where required by the supplier’s documentation.
Contamination Control
Laboratory personnel should also use appropriate contamination-control practices when handling peptide research materials. Storage conditions should not be assumed solely from general peptide guidance, as requirements can vary according to the formulation and product state.
Documentation First
Always prioritise the storage instructions supplied with the specific Sermorelin 10mg batch and the applicable institutional procedures.
Documentation and traceability are also factors to take into account in evaluating Sermorelin 10mg UK suppliers. When a material is identified with a clear compound name, research quantity is specified and batch information is readily available, it is easier to decide if the material is appropriate for a specific laboratory process.
Specifically, analytical transparency is relevant. Confirm that a supplier can supply a batch-specific COA, and can state the testing method and has a system of traceability between the COA and the research product.
Supplier evaluation should also include packaging, storage information, labelling of the product and clear research-use restrictions.
These practical checks offer much more informative information for UK laboratories seeking to procure Sermorelin 10mg than the generic terms “Premium” or “Pharmaceutical grade” are able to provide without adequate substantiation.
Analytical Records
Batch certificates for Sermorelin
Every order ships with the CoA matched to its batch number, and the analytical records
are published here - open the certificate before you order, or cross-check the one in
your parcel.
What exactly does the 10mg figure on Sermorelin mean?
The 10mg figure describes the nominal quantity of Sermorelin research material supplied in this product format. It does not represent a recommended dose, frequency of use or administration amount. Laboratories should determine material requirements from their experimental design, analytical method and approved research protocol.
Is Sermorelin the same compound as growth hormone?
No. Sermorelin is a 29-amino-acid peptide corresponding to the biologically active N-terminal region of human GHRH. Growth hormone is a different hormone. Research involving sermorelin has examined its interaction with GHRH-related signalling and the physiological pathway involved in regulating growth hormone secretion.
Why do researchers investigate a 29-amino-acid GHRH fragment?
The N-terminal 29 residues of human GHRH retain biological activity associated with the parent peptide. This has made GHRH(1-29) useful in investigations of receptor activation, peptide structure–activity relationships, endocrine signalling and peptide stability. Findings depend on the experimental system and should not automatically be translated into therapeutic claims.
What information should appear on a Sermorelin COA?
A useful Certificate of Analysis should enable researchers to connect analytical results with the supplied batch. Relevant details can include product identity, batch or lot reference, testing method, reported analytical results and test information. Researchers should distinguish between identity testing and purity assessment rather than treating a purity percentage alone as complete verification.
Does 10mg make this Sermorelin format more effective than another strength?
No. A 10mg product contains a different quantity of research material; the figure does not demonstrate that it is more effective, biologically stronger or preferable to another product quantity. Selection should be based on the amount required for a laboratory’s planned assays, analytical programme and research protocol.
What is the UK status of research-labelled Sermorelin?
Products marketed as research chemicals are not necessarily an MHRA approved medicine. Authorised medicines are medicines which have been approved for specific uses and have been defined by regulatory documentation in the UK. The Sermorelin that is supplied here is intended only for laboratory research and should not be implied or used as a medication for the treatment of humans.
PG
Medically & Scientifically Reviewed By
Dr. Priyanka Goel
Scientific & Medical Content Reviewer
Reviews research content against current published literature and UK regulatory guidance, ensuring compound information is accurate, referenced and presented for research use only.
Sermorelin 10mg is provided for legitimate laboratory, analytical and scientific research only. Not intended to be eaten, administered by the person or for diagnosis or therapy. The 10mg designation is not a human or animal dosage recommendation, rather it indicates the amount of research material provided. The information provided here is scientific and product characteristics for research only and should not be construed as medical advice.
